EA201492251A1 - Индукция артериогенеза донора no (оксида азота) - Google Patents

Индукция артериогенеза донора no (оксида азота)

Info

Publication number
EA201492251A1
EA201492251A1 EA201492251A EA201492251A EA201492251A1 EA 201492251 A1 EA201492251 A1 EA 201492251A1 EA 201492251 A EA201492251 A EA 201492251A EA 201492251 A EA201492251 A EA 201492251A EA 201492251 A1 EA201492251 A1 EA 201492251A1
Authority
EA
Eurasian Patent Office
Prior art keywords
arteriogenesis
donor
induction
nitrogen oxide
effective amount
Prior art date
Application number
EA201492251A
Other languages
English (en)
Other versions
EA032534B1 (ru
Inventor
Михаэла Горат
Original Assignee
Г. Поль-Боскамп Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Г. Поль-Боскамп Гмбх Унд Ко. Кг filed Critical Г. Поль-Боскамп Гмбх Унд Ко. Кг
Publication of EA201492251A1 publication Critical patent/EA201492251A1/ru
Publication of EA032534B1 publication Critical patent/EA032534B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение среди прочего относится к способу стимулирования коллатерального кровообращения, включающему стадию лечения субъекта терапевтически эффективным количеством донора оксида азота, в котором терапевтически эффективное количество донора оксида азота вызывает артериогенез, достаточный для того, чтобы увеличить коллатеральное кровообращение в физиологическом или патологическом состоянии.
EA201492251A 2012-05-31 2013-05-29 Способ профилактики или лечения артериальной недостаточности EA032534B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261653595P 2012-05-31 2012-05-31
EP12004187.6A EP2668947B1 (en) 2012-05-31 2012-05-31 Induction of arteriogenesis with a nitric oxide-donor such as nitroglycerin
PCT/EP2013/061131 WO2013178715A1 (en) 2012-05-31 2013-05-29 Induction of arteriogenesis with an no (nitric oxide) donor

Publications (2)

Publication Number Publication Date
EA201492251A1 true EA201492251A1 (ru) 2015-05-29
EA032534B1 EA032534B1 (ru) 2019-06-28

Family

ID=46275671

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492251A EA032534B1 (ru) 2012-05-31 2013-05-29 Способ профилактики или лечения артериальной недостаточности

Country Status (13)

Country Link
US (3) US20150164845A1 (ru)
EP (3) EP2668947B1 (ru)
JP (1) JP6280106B2 (ru)
CN (2) CN104519881A (ru)
AU (2) AU2013269631B2 (ru)
CA (1) CA2872465C (ru)
DE (1) DE112013002717T5 (ru)
EA (1) EA032534B1 (ru)
ES (2) ES2617494T3 (ru)
HU (2) HUE033092T2 (ru)
PL (2) PL2668947T3 (ru)
TR (1) TR201908817T4 (ru)
WO (1) WO2013178715A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033092T2 (hu) 2012-05-31 2017-11-28 G Pohl-Boskamp Gmbh & Co Kg Arteriogenezis indukálása nitroglicerinnel mint nitrogén-oxid donorral
CA3040872A1 (en) * 2016-12-14 2018-06-21 G. Pohl-Boskamp Gmbh & Co. Kg Reducing side effects of short acting no donors
TWI650326B (zh) * 2017-10-24 2019-02-11 國立交通大學 醫藥組合物、化合物的用途及合成方法
WO2021073535A1 (zh) * 2019-10-16 2021-04-22 上海岸阔医药科技有限公司 预防或治疗与vegfr和/或vegf被抑制相关疾病的方法
CN110934865A (zh) * 2019-12-06 2020-03-31 牡丹江医学院 一种用于预防和治疗血液透析低血压的药物组合物及其用途

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE632504A (ru) 1962-05-24
GB1205019A (en) 1966-12-07 1970-09-09 Sterwin Ag Improvements in or relating to oral dosage forms
JPS599539B2 (ja) 1979-11-13 1984-03-03 日本化薬株式会社 ニトログリセリン水溶液及びその製造法
CA1163195A (en) 1980-06-26 1984-03-06 Alec D. Keith Polymeric diffusion matrix containing a vasodilator
US4542013A (en) 1981-07-08 1985-09-17 Key Pharmaceuticals, Inc. Trinitroglycerol sustained release vehicles and preparation therefrom
DE3246081A1 (de) 1982-12-13 1984-06-14 G. Pohl-Boskamp GmbH & Co Chemisch-pharmazeutische Fabrik, 2214 Hohenlockstedt Nitroglycerin-spray
US4671953A (en) 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
CA1319099C (en) 1987-01-23 1993-06-15 James A. Nathanson Atriopeptins, guanylate cyclase activators, and phosphodiesterase inhibitors as treatment for glaucoma, hydrocephalus and cerebral edema (cranial fluid volume dysfunction)
JPH0645538B2 (ja) 1987-09-30 1994-06-15 日本化薬株式会社 ニトログリセリンスプレー剤
HU199678B (en) 1988-07-08 1990-03-28 Egyt Gyogyszervegyeszeti Gyar Process for producing aerosols containing nitroglicerol
DE4007705C1 (ru) 1990-03-10 1991-09-26 G. Pohl-Boskamp Gmbh & Co. Chemisch-Pharmazeutische Fabrik, 2214 Hohenlockstedt, De
US5370862A (en) 1990-06-13 1994-12-06 Schwarz Pharma Ag Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina
DE4018919C2 (de) 1990-06-13 1994-08-25 Sanol Arznei Schwarz Gmbh Nitroglycerin-Spray
DE4026072A1 (de) 1990-08-17 1992-02-20 Sanol Arznei Schwarz Gmbh Nitroglycerinhaltiger, hydrophiler, waessriger pumpspray
DE4038203A1 (de) 1990-11-30 1992-06-04 Kali Chemie Pharma Gmbh Pharmazeutische spray-zubereitungen mit coronaraktiven wirkstoffen
US5698589A (en) 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
JPH09504274A (ja) * 1993-09-17 1997-04-28 ブリガム アンド ウィメンズ ホスピタル 人工表面および血管面の血栓を予防する酸化窒素付加物の利用
US5869082A (en) 1996-04-12 1999-02-09 Flemington Pharmaceutical Corp. Buccal, non-polar spray for nitroglycerin
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
US20030095925A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
ATE209911T1 (de) 1997-10-03 2001-12-15 Warner Lambert Co Gepresste nitroglycerintablette und verfahren zu ihrer herstellung
US6796966B2 (en) 1997-10-15 2004-09-28 Jeffrey E. Thomas Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal
WO1999038472A2 (en) 1998-01-28 1999-08-05 Seatrace Pharmaceuticals Inc Topical vasodilatory gel composition and methods of use and production
US5989529A (en) 1998-11-20 1999-11-23 Schering-Plough Healthcare Products, Inc. Substantive topical composition
IT1303793B1 (it) 1998-11-27 2001-02-23 Promefarm S R L "composizione farmaceutica comprendente un composto organico donatoredi ossido nitrico (no)"
US6962691B1 (en) 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
RU2174838C2 (ru) 1999-11-04 2001-10-20 Ивановская государственная медицинская академия Способ лечения тяжелого бронхообструктивного синдрома у детей раннего возраста
US20020049188A1 (en) 1999-12-15 2002-04-25 Azarnoff Daniel L. Nitroglycerin ointment for treatment of pain associated with anal disease
US6443307B1 (en) 2000-01-25 2002-09-03 Michael D. Burridge Medication dispenser with an internal ejector
US20010048987A1 (en) 2000-03-14 2001-12-06 David Kanios Packaging materials for transdermal drug delivery systems
US6538033B2 (en) 2000-08-29 2003-03-25 Huntington Medical Research Institutes Nitric oxide donor compounds
SK15732003A3 (sk) 2001-06-22 2005-01-03 Pfizer Products Inc. Farmaceutické kompozície zahrnujúce liečivá s nízkou rozpustnosťou a/alebo liečivá citlivé na kyselinu a neutralizované kyslé polyméry
JP3984225B2 (ja) 2002-02-08 2007-10-03 ザ プロクター アンド ギャンブル カンパニー 子供用安全袋
US20090118019A1 (en) * 2002-12-10 2009-05-07 Onlive, Inc. System for streaming databases serving real-time applications used through streaming interactive video
US20050095278A1 (en) 2003-01-14 2005-05-05 Viorel Nicolaescu Use of nitroglycerin to relieve nocturnal muscle cramps
US20040228883A1 (en) 2003-02-21 2004-11-18 Mitchell Karl Prepackaged aqueous pharmaceutical formulation for the treatment of cardiac conditions containing at least two different active agents and method of formulation
CA2530843A1 (en) 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
US20070053966A1 (en) 2003-10-17 2007-03-08 Robert Ang Medicated orthopedic support structures for treatment of damaged musculoskeletal tissue
US7781226B2 (en) 2004-02-27 2010-08-24 The Board Of Regents Of The University Of Texas System Particle on membrane assay system
WO2005084301A2 (en) 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
FR2868314B1 (fr) * 2004-04-05 2008-10-24 Therabel Pharmaceuticals Ltd Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables
US20080260861A1 (en) 2004-04-07 2008-10-23 The General Hospital Corporation Modulating Lymphatic Function
US20090221540A1 (en) 2006-01-09 2009-09-03 Pantarhei Bioscience B.V. Method of Treating An Acute Vascular Disorder
CA2649895C (en) 2006-04-19 2013-03-26 Novadel Pharma Inc. Stable hydroalcoholic oral spray formulations and methods
WO2008105731A1 (en) 2007-02-26 2008-09-04 Jon Lundberg New use of nitrites and nitrates and compositions containing these
WO2009077764A1 (en) * 2007-12-18 2009-06-25 Athera Biotechnologies Ab Compounds and methods for the treatment of vascular disease
CN101229148A (zh) 2007-12-28 2008-07-30 天津医科大学 硝酸甘油口腔(舌下)崩解片的制剂及其制备方法
DE102008005484A1 (de) * 2008-01-22 2009-07-23 Schaper, Wolfgang, Dr. Induktion und Förderung der Arteriogenese
PT2098249E (pt) 2008-03-05 2013-01-07 Rivopharm Sa Veículos para nicorandil com estabilidade melhorada
DE202008007318U1 (de) 2008-03-14 2008-07-31 G. Pohl-Boskamp Gmbh & Co. Kg Langzeitstabile pharmazeutische Zubereitung mit dem Wirkstoff Glyceroltrinitrat
US20100184870A1 (en) 2008-03-14 2010-07-22 Rolf Groteluschen Long-term stable pharmaceutical preparation containing the active ingredient glycerol trinitrate
EP2379070A4 (en) 2008-07-21 2013-11-13 Imi Internat Medical Innovations D B A Procris Pharmaceuticals WATER BASED TOPICAL STABLE PHARMACEUTICAL CREAMES AND METHODS FOR PREPARING AND USING SAME
US20120059245A1 (en) 2008-12-23 2012-03-08 Ivo Buschmann Method and device for monitoring and improving arteriogenesis
CA2671029A1 (en) 2009-06-30 2010-12-30 James S. Baldassarre Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
CA2806636C (en) * 2010-08-03 2018-01-23 G. Pohl-Boskamp Gmbh & Co. Kg Use of glyceryl trinitrate for treating traumatic edema
ES2672261T3 (es) * 2011-02-25 2018-06-13 G. Pohl-Boskamp Gmbh & Co. Kg Gránulos estabilizados que contienen trinitrato de glicerilo
US20140057977A1 (en) 2012-05-31 2014-02-27 G. Pohl-Boskamp Gmbh & Co. Kg Induction of Arteriogenesis
EP2668948A1 (en) * 2012-05-31 2013-12-04 G. Pohl-Boskamp GmbH & Co. KG Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
CA2778679A1 (en) * 2012-05-31 2013-11-30 G. Pohl-Boskamp Gmbh & Co. Kg Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
HUE033092T2 (hu) * 2012-05-31 2017-11-28 G Pohl-Boskamp Gmbh & Co Kg Arteriogenezis indukálása nitroglicerinnel mint nitrogén-oxid donorral
US9248099B2 (en) * 2012-05-31 2016-02-02 Desmoid Aktiengesellschaft Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
JP5996371B2 (ja) 2012-10-29 2016-09-21 株式会社東芝 電子機器
EP2805730A1 (en) 2013-05-21 2014-11-26 Bergen Teknologioverforing AS Nitric oxide donor for the treatment of chronic fatigue syndrome
EP2878310B1 (en) 2013-11-29 2017-01-11 G. Pohl-Boskamp GmbH & Co. KG Sprayable aqueous composition comprising glyceryl trinitrate
CA3040872A1 (en) 2016-12-14 2018-06-21 G. Pohl-Boskamp Gmbh & Co. Kg Reducing side effects of short acting no donors

Also Published As

Publication number Publication date
JP2015518030A (ja) 2015-06-25
AU2013269631B2 (en) 2018-03-01
DE112013002717T5 (de) 2015-02-26
ES2617494T3 (es) 2017-06-19
US11166931B2 (en) 2021-11-09
EP2877170B1 (en) 2019-04-10
AU2018200831A1 (en) 2018-02-22
EP3412285A2 (en) 2018-12-12
EP3412285A3 (en) 2019-02-20
WO2013178715A1 (en) 2013-12-05
US20170172966A1 (en) 2017-06-22
PL2877170T3 (pl) 2019-11-29
EP2668947A1 (en) 2013-12-04
US20150164845A1 (en) 2015-06-18
EA032534B1 (ru) 2019-06-28
JP6280106B2 (ja) 2018-02-14
CN110251500A (zh) 2019-09-20
PL2668947T3 (pl) 2017-06-30
AU2013269631A1 (en) 2014-11-13
ES2731664T3 (es) 2019-11-18
EP2668947B1 (en) 2016-11-30
US20220096417A1 (en) 2022-03-31
CA2872465C (en) 2021-02-16
TR201908817T4 (tr) 2019-07-22
CA2872465A1 (en) 2013-12-05
HUE044056T2 (hu) 2019-09-30
HUE033092T2 (hu) 2017-11-28
EP2877170A1 (en) 2015-06-03
CN104519881A (zh) 2015-04-15

Similar Documents

Publication Publication Date Title
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
PH12015502075B1 (en) Treatment of cataplexy
EA201890411A1 (ru) Терапевтически активные соединения и способы их применения
TW201611843A (en) Methods of treatment with arginine deiminase
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2016013635A (es) Métodos para aumentar los niveles de eritrocitos y tratar de la enfermedad de células falciformes.
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
ZA201706402B (en) C.novyi for the treatment of solid tumors in humans
EA201492251A1 (ru) Индукция артериогенеза донора no (оксида азота)
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
EA201590883A1 (ru) Лечение помалидомидом рака у субъекта с почечной недостаточностью
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
EA201591434A1 (ru) Способ обеспечения глазной нейропротекции
BR112016012248A2 (pt) método de tratamento de nefropatia
MX2016015907A (es) Metodos y composiciones para tratar desordenes por deficiencia de oxido nitrico y condiciones relacionadas.
EA201690446A1 (ru) Лечение множественной миеломы
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
EA201690445A1 (ru) Лечение рака

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ